{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:12:37Z","timestamp":1790341957678,"version":"4.1.0"},"reference-count":72,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Metastatic non\u2013small cell lung cancer (NSCLC) is highly heterogeneous, and there are patients with limited areas of metastases (oligometastases) or progression (oligoprogression) whose natural history and prognosis can be considerably more favorable. As a result, local therapy may offer these patients a chance at clinically meaningful disease control and\/or cure. This review begins by describing the current status of the existing prospective data, including evidence of overall survival improvements from multiple randomized trials. Given the nascence of this realm, the review then examines ongoing controversies and unresolved issues regarding local therapy for oligometastatic and oligoprogression. First, the role of local therapy in the setting of targeted therapies and immunotherapy is discussed, because most published randomized trials of local therapy have been performed in the context of chemotherapy, which is no longer the standard of care for most patients with metastatic NSCLC. Refining patient selection for local therapy is then reviewed, including clinical factors (such as control of the primary and regional lymph node sites, the heterogeneous definitions of oligometastases\/oligoprogression, and the underrepresentation of brain metastases in existing randomized data) and novel pathologic\/molecular biomarkers. Next, because there also remains no consensus regarding the optimal modality of local therapy, the advantages and disadvantages of stereotactic radiotherapy, surgery, and other ablative techniques are discussed. Subsequently, methods to optimize radiotherapy are examined, including controversies regarding the optimal dose\/fractionation and timing\/sequencing scheme. A discussion regarding potentially extending the existing data to polymetastatic NSCLC follows. The review concludes with remarks regarding prudently designing randomized trials of local therapy going forward, including the benefits and drawbacks of specific endpoints meriting further testing in this unique population.<\/jats:p>","DOI":"10.6004\/jnccn.2021.7117","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T19:50:20Z","timestamp":1652298620000},"page":"531-539","source":"Crossref","is-referenced-by-count":22,"title":["Optimize Local Therapy for Oligometastatic and Oligoprogressive Non\u2013Small Cell Lung Cancer to Enhance Survival"],"prefix":"10.6004","volume":"20","author":[{"given":"Joe Y.","family":"Chang","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Verma","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref31","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1158\/2326-6066.CIR-18-0793","article-title":"Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses","volume":"7","author":"Welsh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ijrobp.2021.09.014","article-title":"Consolidative use of radiotherapy to block (CURB) oligoprogression\u2014interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast","volume":"111","author":"Tsai","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref571","first-page":"278","article-title":"Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence","volume":"100","author":"Hughes","year":"1986","journal-title":"Surgery"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"737425","DOI":"10.3389\/fonc.2021.737425","article-title":"Pulsed radiation therapy to improve systemic control of metastatic cancer","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ijrobp.2021.09.014","article-title":"Consolidative use of radiotherapy to block (CURB) oligoprogression\u2014interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast","volume":"111","author":"Tsai","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.ijrobp.2008.03.044","article-title":"Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy","volume":"72","author":"Milano","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer","volume":"15","author":"Ashworth","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2021.08.005","article-title":"Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC","volume":"163","author":"Farooqi","year":"2021","journal-title":"Radiother Oncol"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ijrobp.2014.07.012","article-title":"Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy","volume":"90","author":"Sheu","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ijrobp.2018.04.054","article-title":"Safety of combined immunotherapy and thoracic radiation therapy: analysis of 3 single-institutional phase I\/II trials","volume":"101","author":"Verma","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s10585-014-9664-3","article-title":"Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs","volume":"31","author":"Uppal","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijrobp.2020.08.025","article-title":"Use of multi-site radiation therapy for systemic disease control","volume":"109","author":"Patel","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2021.09.022","article-title":"American Radium Society appropriate use criteria for oligometastatic and oligoprogressive non\u2013small cell lung cancer","volume":"112","author":"Amini","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.ijrobp.2018.06.340","article-title":"Nano-based quantification of circulating tumor cells as a biomarker of disease status in oligometastatic patients following metastases-directed radiation therapy","volume":"102","author":"Lindsay","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s10585-014-9664-3","article-title":"Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs","volume":"31","author":"Uppal","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1470-2045(08)70155-4","article-title":"Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study)","volume":"9","author":"Lencioni","year":"2008","journal-title":"Lancet Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-5223(97)70397-0","article-title":"Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases","volume":"113","author":"Pastorino","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/annonc\/mdu584","article-title":"A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann Oncol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref61","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC [published online January 30, 2022]","author":"Wang","journal-title":"J Natl Cancer Inst"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-5223(97)70397-0","article-title":"Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases","volume":"113","author":"Pastorino","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2021.09.022","article-title":"American Radium Society appropriate use criteria for oligometastatic and oligoprogressive non\u2013small cell lung cancer","volume":"112","author":"Amini","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1158\/2326-6066.CIR-18-0793","article-title":"Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses","volume":"7","author":"Welsh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"ref81","article-title":"Local consolidative therapy versus systemic therapy alone for metastatic non-small cell lung cancer: a systematic review and meta-analysis [published online February 20, 2022]","author":"Wu","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.ijrobp.2018.06.340","article-title":"Nano-based quantification of circulating tumor cells as a biomarker of disease status in oligometastatic patients following metastases-directed radiation therapy","volume":"102","author":"Lindsay","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","article-title":"Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs","volume":"13","author":"Xu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ijrobp.2018.04.054","article-title":"Safety of combined immunotherapy and thoracic radiation therapy: analysis of 3 single-institutional phase I\/II trials","volume":"101","author":"Verma","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/annonc\/mdu584","article-title":"A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann Oncol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2020.06.015","article-title":"Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials","volume":"136","author":"Pasalic","year":"2020","journal-title":"Eur J Cancer"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","article-title":"Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs","volume":"13","author":"Xu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ijrobp.2014.07.012","article-title":"Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy","volume":"90","author":"Sheu","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2021.08.005","article-title":"Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC","volume":"163","author":"Farooqi","year":"2021","journal-title":"Radiother Oncol"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"e001001","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijrobp.2020.08.025","article-title":"Use of multi-site radiation therapy for systemic disease control","volume":"109","author":"Patel","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","article-title":"Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?","volume":"13","author":"Bernstein","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of radiation therapy in modulation of the tumor stroma and microenvironment","volume":"10","author":"Menon","year":"2019","journal-title":"Front Immunol"},{"key":"ref421","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC [published online January 30, 2022]","author":"Wang","journal-title":"J Natl Cancer Inst"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1470-2045(08)70155-4","article-title":"Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study)","volume":"9","author":"Lencioni","year":"2008","journal-title":"Lancet Oncol"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","article-title":"Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?","volume":"13","author":"Bernstein","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"ref211","first-page":"278","article-title":"Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence","volume":"100","author":"Hughes","year":"1986","journal-title":"Surgery"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"737425","DOI":"10.3389\/fonc.2021.737425","article-title":"Pulsed radiation therapy to improve systemic control of metastatic cancer","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref441","article-title":"Local consolidative therapy versus systemic therapy alone for metastatic non-small cell lung cancer: a systematic review and meta-analysis [published online February 20, 2022]","author":"Wu","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer","volume":"15","author":"Ashworth","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.radonc.2021.06.037","article-title":"High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial","volume":"162","author":"Patel","year":"2021","journal-title":"Radiother Oncol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"e001001","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.ijrobp.2008.03.044","article-title":"Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy","volume":"72","author":"Milano","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2020.06.015","article-title":"Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials","volume":"136","author":"Pasalic","year":"2020","journal-title":"Eur J Cancer"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of radiation therapy in modulation of the tumor stroma and microenvironment","volume":"10","author":"Menon","year":"2019","journal-title":"Front Immunol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.radonc.2021.06.037","article-title":"High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial","volume":"162","author":"Patel","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/5\/article-p531.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/5\/article-p531.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T18:40:28Z","timestamp":1652467228000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/5\/article-p531.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":72,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2021.7117","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}